Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study by Woo, Jong-Min et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2014
Importance of remission and residual somatic
symptoms in health-related quality of life among
outpatients with major depressive disorder: a cross-
sectional study
Jong-Min Woo
Hong Jin Jeon
See next page for additional authors
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Woo et al.: Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major
depressive disorder: a cross-sectional study. Health and Quality of Life Outcomes 2014 12:188.
Available at: https://doi.org/10.1186/s12955-014-0188-y
Authors
Jong-Min Woo, Hong Jin Jeon, Eunsun Noh, Hyo-Jin Kim, Sun Woo Lee, Kyung Kyu Lee, Sung Hwan Kim,
and Jin Pyo Hong
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/134
RESEARCH Open Access
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symptoms in health-related quality of life among
outpatients with major depressive disorder: a
cross-sectional study
Jong-Min Woo1,2, Hong Jin Jeon3,4, Eunsun Noh5,6, Hyo-Jin Kim7, Sun Woo Lee8, Kyung Kyu Lee9,
Sung Hwan Kim10 and Jin Pyo Hong11*
Abstract
Background: Major depressive disorder (MDD) is strongly associated with an impaired quality of life (QoL), which is
itself affected by various factors. Symptom-oriented ratings poorly reflect the impact of disease on the QoL and
level of functioning of the mental health of subjects. The purpose of this study was to assess health-related QoL
(HRQoL) using preference-based measures in outpatients with MDD with regard to their remission achievement
and clinical factors affecting the HRQoL.
Methods: This was a cross-sectional observational study. We recruited 811 patients with MDD from 14 psychiatric
outpatient clinics in Korea. They were divided into three groups as follows: a new visit group (n = 287), a remitted
group (n = 235), and a non-remitted group (n = 289). The 17-item Hamilton Depression Rating Scale was used to
assign patients to the remitted or non-remitted group. The general HRQoL was assessed with the EuroQol 5D
(EQ-5D), using both the EQ-5D index score and the EuroQol Visual Analog Scale (EQ-VAS). The disease-specific
HRQoL was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF).
Results: The non-remitted group showed a significant impairment of HRQoL in view of the subscales of EQ-5D index
scores, EQ-VAS, and Q-LES-Q-SF. The EQ-5D index score in the remitted group was 0.77 ? 0.10, while it was 0.57 ? 0.23
in the non-remitted group and 0.58 ? 0.24 in the new visit group (p < 0.0001). The EQ-VAS scores for the remitted and
non-remitted groups were 72.5 ? 16.6 and 50.9 ? 20.3, respectively (p < 0.0001). Likewise, patients with remission had
the Q-LES-Q-SF total score of 46.5 ? 8.8, whereas tho se with non-remission reported 36.7 ? 7.7 (p < 0.0001). The
symptom severity measured by the Depression and Somatic Symptoms Scale was significantly correlated with the
HRQoL. Furthermore, patients with severe somatic symptoms showed a significantly lower EQ-5D index score
(0.54 ? 0.24) than those with mild/moderate somatic symptoms (0.75 ? 0.12; p = 0.002).
Conclusion: Non-remitted MDD patients, especially those with more severe somatic symptoms, show a distinct
impairment of HRQoL and more clinical symptoms, suggesting the importance of achieving remission in the
treatment of MDD.
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Introduction
Major depressive disorder (MDD) is strongly associated
with an impaired quality of life (QoL) and several studies
have investigated the factors affecting this relationship
[1-3].
Health related QoL (HRQoL) covers a wide range of
dimensions including psychological status, functional abil-
ities, subjective well-being, social interactions, role per-
formance and physical health [4]. Due to this nature of
HRQoL, assessment of HRQoL has received considerable
research attention and provided potential for a more com-
prehensive evaluation of treatment outcomes.
However, symptom-oriented ratings poorly reflect the
impact of mental health on QoL and level of function-
ing. Thus, QoL has been mainly assessed with patient-
reported outcome (PRO) instruments. Recently, the
importance of PRO measures in clinical trials for new
drug, biologic agents and devices was underscored by the
release of the US Food and Drug Administration's draft
guidance for industry [5,6].
Recently, results of the Factors Influencing Depression
Endpoints Research (FINDER) study of the European
Union demonstrated that antidepressant treatment was
associated with an improved HRQoL and that clinical fac-
tors, including the presence of somatic and painful symp-
toms, were negatively associated with HRQoL [1,7,8].
Depressed patients who fail to obtain full remission, which
is defined as almost full recovery of depression symptoms
to the level of a person without depression, show a higher
risk of being depressed again and continue to experience
functional impairment [9]. These results suggest that
achieving remission and severity of certain residual symp-
toms can be more important for improving QoL.
Previous studies suggested an impaired HRQoL in pa-
tients with depression and an improved HRQoL in treated
patients; however, the relationship between HRQoL, par-
ticularly measured using PRO and remission status is less
well understood. In our current study, we quantified both
generic and disease-specific measures of QoL and then
compared them among three subgroups (new visit, remit-
ted, and non-remitted groups). In addition, we examined
the effect of HRQoL on suicidal thoughts and suicide at-
tempts. We hypothesized that the non-remitted group
would show more severe impairment in QoL than the
new visit group and remitted group and, moreover, that
the severity of somatic and pain symptoms would be
closely associated with both generic and disease-specific
QoL measures.
Methods
Subjects
The data of Korean patients with MDD were derived from
the Korean Burden of Illness Study. This study was a non-
interventional, multicenter-based, naturalistic observational,
cross-sectional, and outpatient-based study of patients with
MDD. All patients were enrolled from 14 regional psychi-
atric outpatient clinics in Korea. The study was conducted
between December 2011 and September 2012. All study
procedures were approved by the Institutional Review
Board of Asan Medical Center and other sites. Written
informed consent was obtained from all study patients
before study initiation.
Inclusion and exclusion criteria
Patients 18 years or older and meeting the DSM-IV cri-
teria for a single or recurrent non-psychotic MDD were
included. Each consecutive patient was evaluated accord-
ing to the inclusion and exclusion criteria and was then
allocated to one of three groups: (1) a new visit group, (2)
a remitted group (17-item Hamilton Depression Rating
Scale [HAM-D-17] <8), or (3) a non-remitted group
(HAM-D-17 ≥ 8). Each hospital was allowed to consecu-
tively allocate approximately eight patients to each group.
Groups 2 and 3 included patients who had received MDD
treatment for less than 6 months in order to exclude any
bias possibility in calculating the lost productivity costs
due to decreased social occupational function related to
other emotional problems.
Exclusion criteria included history of bipolar disorder,
schizophrenia, schizoaffective disorder, psychosis, anorexia
or bulimia nervosa, obsessive-compulsive disorder, or a
serious general medical condition.
Measurement of depressive symptoms
The 17-item HAM-D was used to measure the severity of
depressive symptoms at each visit [10]. The HAM-D-17 is
a clinician-administered depression assessment scale, evalu-
ating mood and vegetative symptoms [10]. Each item was
rated with a score of 0-4 (where the scores are equivalent
to absent, doubtful/trivial, mild, moderate and severe) or
0? 2 (absent, doubtful/mild, and obvious, distinct/severe)
[10]. By summing the score of each item, the total scores
for HAM-D-17 can range from 0 to 54. In general, a total
HAM-D-17 score of 7 or less is accepted as an indicator of
remission [11]. It has been reported an internal consistency
of 0.83 [12], inter-rater reliability of 0.97 [13], and test-
retest reliability of 0.81 [14], showing adequate reliability.
Measurement of somatic symptoms
The Depression and Somatic Symptoms Scale (DSSS) was
applied to measure somatic symptoms in MDD patients
[15]. The DSSS is a 22-item self-administered rating scale
containing three subscales: a Depression Subscale (DS), a
Pain Subscale (PS), and a Somatic Subscale (SS). The DS
has 12 items, including three vegetative symptoms and fa-
tigue, whereas the SS has 10 items, including five pain
items composed of the 5-item PS. Each item was rated
with a score of 0? 3: 0 (not at all), 1 (mild), 2 (moderate),
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or 3 (severe). Thus, the range of summed scores was 0? 66.
The scale shows a good validity and reliability, with higher
scores indicating stronger symptoms. The Korean Version
of DSSS has a Cronbach's alpha of 0.90 and shows a rela-
tively high test-retest reliability (r = 0.83, p < 0.01) [16,17].
Measures of QoL
In order to assess HRQoL, we used generic instruments,
including the European Quality of Life-5 Dimensions
(EQ-5D; containing an index score and visual analog scale
[VAS]), and disease- or condition-specific QoL measures,
including the Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q).
EuroQol (EQ-5D and EQ-VAS)
EQ-5D is a standardized preference-based measure of
health status developed by the EuroQol Group that is
applicable to mental health conditions such as mild to
moderate depression and anxiety [18-20]. The EQ-5D
was developed to provide a simple, generic measure of
health for clinical and economic appraisals [20]. It pro-
vides a simple descriptive profile and a single index
value for health status that can be used in the clinical
and economic evaluation of health care as well as in
population health surveys. The EQ-5D is designed for
self-completion by respondents and essentially consists
of two pages. The EQ-5D descriptive system comprises
the following five dimensions (with three levels) and the
EQ visual analog scale (EQ-VAS). The EQ-5D consists
of five dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression), each with three
levels of severity in health utility (no problems/some or
moderate problems/extreme problems) recording an in-
dividual ? s ratings of EQ-5D health states. The Korean
version of the EQ-5D was developed and validated by
Kim et al. in 2005 [21]. The EQ-5D index score was cal-
culated based on the weights elicited from a large na-
tional survey of the Korean population [22].
The Q-LES-Q
The Q-LES-Q is a self-report instrument designed to
measure satisfaction and enjoyment in various domains
of functioning (e.g., physical health, work, and household
duties) [23]. It can be applied to depressed individuals
[24]. Many studies have used the Q-LES-Q to measure
life satisfaction and enjoyment in patients with depres-
sion during pre- and post-treatment phases [23,25,26].
The Q-LES-Q Short Form (Q-LES-Q-SF) used in this
study consists of 16 items, of which the first 14 assess
discrete domains such as social relationships, living or
housing situation, and physical health. Item 15 concerns
the respondents? satisfaction with medication they are tak-
ing, if applicable. Item 16 is a global rating in which re-
spondents are asked to rate their ? overall life satisfaction
and contentment.? Each item is scored on a 5-point Likert
scale that indicates the degree of enjoyment or satisfaction
achieved during the past week (1 = very poor, 5 = very good).
Higher scores indicate better function. Items 1 through 14
of the Q-LES-Q-SF can be summed to obtain a total score,
with higher scores indicating greater life enjoyment and sat-
isfaction. For the present analyses, we used the total score
generated by the sum of the first 14 items. This scale has a
Cronbach?s alpha of 0.90 and a test-retest reliability of 0.74
[23]. The construct validity of the Q-LES-Q is supported by
moderately negative correlations with the Clinical Global
Impressions? Severity of Illness scale (CGI-S) (r = ? 0.62 for
the summary scale) and the 17-item HAM-D, compared in
a depressed population [23]. To compare with other instru-
ments of HRQoL we also obtained the Q-LES-Q index score
by converting the Q-LES-Q total score to a percentage.
Measures of suicidal thoughts and suicide attempts
We assessed suicide attempts and suicidal thoughts
during the past month before study inclusion using the
Korean version of the Mini-International Neuropsychi-
atric Interview (MINI) suicidality module [27]. The MINI
suicidality module is composed of six questions including
wish for death, wish for self-harm, suicidal thoughts, sui-
cide plans, suicide attempts in the past month, and life-
time suicide attempts. We included the Mini-C2 (suicide
attempts in the past month) and Mini-C3 (suicidal
thoughts) in the analysis to examine the association
between HRQoL and suicidal thoughts/suicide attempts.
Statistical analysis
Descriptive statistics (mean, standard deviation) were
obtained for continuous data in each MDD patient
group. ANOVA (or Kruskal-Wallis test) was performed
to compare the patient groups. Tukey ? s multiple com-
parison method was used for post-hoc group compari-
sons after the significance for ANOVA was determined.
The QoL was compared between the MDD patient
groups using ANCOVA, controlling for the depression
symptom score as covariate. The association between
the QoL and depression symptoms score was evaluated
by stepwise regression using the full set of variables of
the DSSS adjusted by age and sex. Additionally, the asso-
ciation between suicidal thoughts/suicide attempts and
HRQoL using logistic regression analysis was adjusted
by age and DSSS score. Frequency and percentage were
obtained for categorical data and the chi-square test was
applied to the categorical data. All analyses were per-
formed using SAS? version 9.2 (SAS Institute, Cary, NC).
Results
Baseline characteristic of the study subjects
A total of 811 patients with MDD were included in this
study, 235 in the remitted group, 289 in the non-remitted
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group, and 287 in the new visit group. The demographics
and clinical characteristics of study subjects are presented
in Table 1. Approximately 70% of the patients were women
in each group and the mean age ranged from 44.4 to 47.6
years across the groups. There were 62.3% unemployed
subjects in the non-remitted group while the remitted
group showed an unemployment rate of 57.4%. In addition,
patients in the non-remitted group demonstrated a slightly
higher number of depressive episodes than the patients in
the remitted group (mean ? standard deviation [SD], 1.3 ?
2.2 vs. 1.7 ? 2.6) and a slightly longer duration of MDD
(7.3 ? 16.6 vs. 8.1 ? 20.5 months).
Disease severity of the subjects
Table 2 shows the symptom severity measured by 17-
item HAM-D scores and DSSS. Patients who achieved
remission showed a HAM-D score of 4.5 ? 2.1, which is
significantly lower than the scores of the non-remitted
group (16.6 ? 5.8) and the new visit group (17.8 ? 7.0)
(p < 0.0001). Similarly, the total scores of depressive and
somatic symptoms were significantly lower in the remit-
ted group than in the non-remitted and new visit group.
The depressive symptom scores in the remitted group
were 5.9 ? 5.3, whereas they were 16.8 ? 7.2 in the non-
remitted group and 17.4 ? 7.2 in the new visit group
(p < 0.0001). In addition, the total score of somatic symp-
toms including pain was 4.0 ? 3.9 in the remitted group,
10.6 ? 6.2 in the non-remitted group, and 10.9 ? 5.8 in the
new visitors (p < 0.0001).
HRQoL
The HRQoL measured by the EQ-5D index and EQ-
VAS and the disease-specific QoL measured by the Q-
LES-Q-SF are described in Table 3. The EQ-5D index
score was 0.77 ? 0.10 in the remitted group and 0.57 ?
0.23 in the non-remitted group (p < 0.0001). Pain/dis-
comfort and anxiety/depression were the two strongest
influencers of patients' HRQoL among each dimension
of EQ-5D. Approximately 65% of patients in remission
reported no problems with pain/discomfort, whereas
more than 66% of patients in the non-remitted group
reported some/severe problems with pain/discomfort.
Similar to the pain/discomfort domain, approximately
61% of the remitted group reported no problems with
Table 1 Demographics of the study subjects in the new visit, remitted, and non-remitted MDD groups
New MDD (N = 287) Remitted MDD (N = 235) Non-remitted MDD (N = 289) p-value Testa
Sex, n (%)
Male 87 (30.3) 60 (25.5) 84 (29.1) NS
Female 200 (69.7) 175 (74.5) 205 (70.9)
Age (years) 44.4 ? 13.6 47.6 ? 11.8 44.8 ? 13.3 0.0111 b a = c < b
Marital status, n (%)
Single 63 (22.0) 36 (15.3) 62 (21.5) NS
Married 184 (64.1) 165 (70.2) 182 (63.0)
Bereaved 11 (3.8) 12 (5.1) 21 (7.3)
Divorced 24 (8.4) 15 (6.4) 18 (6.2)
Separated 4 (1.4) 7 (3.0) 6 (2.1)
Education, n (%)
Elementary school 40 (13.9) 32 (13.6) 46 (15.9) NS
Middle school 51 (17.8) 31 (13.2) 38 (13.1)
High school 107 (37.3) 105 (44.7) 121 (41.9)
University 81 (28.2) 56 (23.8) 72 (24.9)
Graduate school 7 (2.4) 11 (4.7) 12 (4.2)
Job status, n (%)
Employed 128 (44.6) 100 (42.6) 109 (37.7) NS
Unemployed 159 (55.4) 135 (57.4) 180 (62.3)
Onset of MDD (years) 41.6 ? 14.2 44.7 ? 12.6 41.3 ? 14.2 0.0111 b a = c < b
Number of depressive episodes 1.1 ? 2.0 1.3 ? 2.2 1.7 ? 2.6 0.0131 b a = b, b = c, a < c
Duration of depression (months) 6.3 ? 13.7 7.3 ? 16.6 8.1 ? 20.4 NS
MDD =major depressive disorder; NS = not significant.
aTukey ? s post-hoc test.
bDifference among MDD groups (ANOVA).
Note: Data are represented as mean ? standard deviation or number of patients (%).
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anxiety/depression, whereas 87.2% of the non-remitted
group documented some/severe problems. The HRQoL
measured by EQ-VAS was comparable to the EQ-5D
index score in each group; it was 72.5 ? 16.6 in the re-
mitted group and 50.9 ? 20.3 in the non-remitted group
(p < 0.0001). Life satisfaction measured by Q-LES-Q-SF
was approximately 10 points higher in the remitted
group than in the non-remitted group (46.5 ? 8.8 vs.
36.7 ? 7.7; p < 0.0001). More than 95% of MDD patients
were treated with antidepressant medication and 70.8%
of the remitted group were satisfied/very satisfied with
their antidepressant medication therapy. However, only
41.8% of non-remitted patients reported that they were
satisfied/very satisfied with their medication.
Relationship between depression subscales and HRQoL
The results of multiple stepwise regression analysis be-
tween the HRQoL and depression subscales are demon-
strated in Table 4. When adjusted for age and sex, the
symptom severity measured by the DSSS was significantly
associated with the HRQoL. The EQ-5D index score de-
creased by 0.004 in the remitted group (p = 0.0340) and
0.017 in the non-remitted group (p < 0.0001) for every
unit increase in the somatic symptom score.
Table 5 presents the HRQoL by the level of somatic
symptoms in patients over 40 years of age. Depressed
adults with severe somatic symptoms (≥8) reported a
significantly lower EQ-5D index score than those with
mild/moderate somatic symptoms (<8). This is shown
through the severity of their somatic symptoms: 0.54 ?
0.24 in those with severe symptoms versus 0.75 ? 0.12 in
those with mild/moderate symptoms (p = 0.0017), if
adjusted for depression symptoms. Specifically, patients
with mild/moderate somatic symptoms showed an EQ-5D
index score of 0.72 ? 0.14 in the non-remitted group, close
to the average EQ-5D index score in the remitted group.
Regarding disease-specific HRQoL, patients with severe
somatic symptoms presented an approximately 20% lower
mean difference in the Q-LES-Q-SF index score than
those with mild/moderate somatic symptoms (0.38 ? 0.14
vs. 0.48 ? 0.13).
Association between HRQoL and suicidal thoughts/suicide
attempts
Depression severity and impaired HRQoL were signifi-
cantly associated with an increased risk of suicidal
thoughts and suicide attempts (Table 6). Non-remitted
patients showed a significantly higher risk of having
suicidal thoughts during the past month than those in
remission (odds ratio [OR] 2.55; 95% confidence inter-
val [CI], 1.50 ? 4.33; p = 0.0006). Similarly, non-remitted
patients showed a significantly higher risk of having made
a suicide attempt during the past month than those in re-
mission (OR 2.14; 95% CI, 1.08? 4.25; p = 0.0289). Further-
more, a one-unit improvement in the EQ-5D index score
had a 70% odds reduction of suicidal thoughts (OR 0.3;
95% CI 0.12? 0.75; p = 0.0104) and a 79% odds reduction
of suicide attempts (OR 0.21; 95% CI 0.08 ? 0.57;
p = 0.0023) in depressed patients.
Discussion
Overall results
Here, we examined the HRQoL by the remission status of
depressed patients in Korea. In the present study, the non-
remitted group showed a significant impairment in HRQoL
in view of the subscales of EQ-5D index scores and the EQ-
VAS. Similarly, the life satisfaction measured by the Q-LES-
Q-SF was significantly lower in the non-remitted group than
Table 2 Severity of depressive and somatic symptoms
New MDD (N = 287) Remitted MDD (N = 235) Unremitted MDD (N = 289) p-value Testa
HAM-D scores 17.8 ? 7.0 4.5 ? 2.1 16.6 ? 5.8 <0.0001 b b < c < a
Bech scoresc 8.1 ? 3.5 2.0 ? 1.6 7.5 ? 2.9 <0.0001 b b < c < a
Maier-Philipp scoresd 8.2 ? 3.7 1.8 ? 1.5 7.4 ? 3.2 <0.0001 b b < c < a
Gibbons scorese 10.7 ? 4.6 2.5 ? 1.7 10.0 ? 4.1 <0.0001 b b < c = a
Suicidality scores 9.3 ? 8.3 6.9 ? 7.4 10.8 ? 8.8 0.0008 b a = b, a = c, b < c
DS score 17.4 ? 7.2 5.9 ? 5.3 16.8 ? 7.2 <0.0001 b a = c < b
SS score 10.9 ? 5.8 4.0 ? 3.9 10.6 ? 6.2 <0.0001 b a = c < b
PS score 5.2 ? 3.1 2.2 ? 2.2 5.1 ? 3.4 <0.0001 b a = c < b
DSSS total score 28.2 ? 11.8 9.9 ? 8.5 27.3 ? 12.3 <0.0001 b a = c < b
MDD =major depressive disorder; HAM-D = Hamilton depression rating scale; DSSS = depression and somatic symptoms scale; DS = depression subscale of the
DSSS; SS = somatic subscale of the DSSS; PS = pain subscale of the DSSS.
aTukey ? s post-hoc test.
bDifference among MDD groups (ANOVA).
cDepressed mood, feeling of guilt, work and activities, retardation, anxiety/psychic, and general somatic symptoms are included.
dDepressed mood, feeling of guilt, work and activities, retardation, agitation, and anxiety/psychic are included.
eDepressed mood, feeling of guilt, suicide, work and activities, anxiety/psychic, agitation, anxiety (somatic), and genital symptoms are included.
Note: Data was represented as mean ? standard deviation.
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Table 3 HRQoL (EQ-5D, EQ-VAS, Q-LES-Q-SF)
New MDD (N = 287) Remitted MDD (N = 235) Non-remitted MDD (N = 289) p-value Testa
EQ-5D dimensions mobility, n (%)
No problems 246 (85.7) 219 (93.2) 237 (82.0)
Some problems 35 (12.2) 16 (6.8) 49 (17.0)
Severe problems 6 (2.1) 0 (0.0) 3 (1.0)
Self-care, n (%)
No problems 268 (93.4) 228 (97.0) 267 (92.4)
Some problems 19 (6.6) 7 (3.0) 21 (7.3)
Severe problems 0 (0.0) 0 (0.0) 1 (0.3)
Usual activity, n (%)
No problems 155 (54.0) 201 (85.5) 143 (49.5)
Some problems 119 (41.5) 33 (14.0) 130 (45.0)
Severe problems 13 (4.5) 1 (0.4) 16 (5.5)
Pain/discomfort, n (%)
No problems 98 (34.1) 153 (65.1) 96 (33.2)
Some problems 163 (56.8) 79 (33.6) 152 (52.6)
Severe problems 26 (9.1) 3 (1.3) 41 (14.2)
Anxiety/depression, n (%)
No problems 28 (9.8) 143 (60.9) 37 (12.8)
Some problems 189 (65.9) 90 (38.3) 192 (66.4)
Severe problems 70 (24.4) 2 (0.9) 60 (20.8)
EQ-5D index scorec 0.58 ? 0.24 0.77 ? 0.10 0.57 ? 0.23 <0.0001 b a = c < b
EQ-VAS 50.3 ? 20.6 72.5 ? 16.6 50.9 ? 20.3 <0.0001 b a = c < b
Q-LES-Q-SF total scored 35.6 ? 7.8 46.5 ? 8.8 36.7 ? 7.7 <0.0001 b a = c < b
Q-LES-Q-SF index scoree 0.39 ? 0.14 0.58 ? 0.16 0.41 ? 0.14 <0.0001 b a = c < b
Status of concomitant medication, n (%)
Yes 96 (33.4) 226 (96.2) 280 (96.9)
No 191 (66.6) 9 (3.8) 9 (3.1)
Satisfaction with medication, n (%)
Very dissatisfied 2 (2.1) 0 (0.0) 5 (1.8)
Dissatisfied 33 (34.4) 14 (6.2) 52 (18.6)
Fair 32 (33.3) 52 (23.0) 106 (37.9)
Satisfied 27 (28.1) 136 (60.2) 106 (37.9)
Very satisfied 2 (2.1) 24 (10.6) 11 (3.9)
Overall life satisfaction and contentment, n (%)
Very poor 42 (14.6) 1 (0.4) 27 (9.3)
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in the remitted group. Even though patients in both groups
were treated for their current symptoms of depression, pa-
tients who did not reach the treatment goals showed a sig-
nificantly worse HRQoL than those who met the goals.
This finding may suggest that remission achievement in
depression plays an important role in the improvement in
the preference-based outcomes of patients.
Impact of disease severity on HRQoL
Previous research in France assessing the HRQoL using
the EQ-5D in primary care settings reported EQ-5D
index scores of 0.85 for patients in remission, 0.72 for
non-remitted patients, and 0.58 for patients who had
not responded to the treatment at the 8-week follow-up
[28]. Moreover, the FINDER study documenting the im-
pact of antidepressant medication treatment on patients'
HRQoL found mean EQ-5D index scores of 0.75 at the
6-month follow-up [8]. Several other studies evaluating
HRQoL in depressed patients using various instruments
also presented similar utility scores when patients
achieved remission: 0.79 measured by McSad [29], 0.70
by quality of well-being [30], and 0.74 by the standard
gamble method [31].
In our study, the generic HRQoL measured via the
EQ-5D in the remitted group was consistent with the
previous research; however, the HRQoL in the non-
remitted group was lower than that of previous studies.
The EQ-5D index score in our present study was similar
to the estimated EQ-5D value of the treatment non-
respondent group in the study conducted by Sapin
et al. [28]. There is evidence suggesting that having de-
pression impairs the HRQoL [32] and that antidepressant
medication therapy helps to improve HRQoL in depressed
patients by decreasing MDD symptoms [8,33]. In our
current study, whilst more than 95% of patients in both
the remitted and non-remitted groups were treated with
antidepressant medication, satisfaction toward their medi-
cation was lowered in the non-remitted group: one of
every five patients in the non-remitted group was dis-
satisfied with their medication use and only 42% expressed
satisfaction in this group. Thus, most patients in the non-
remitted group may not respond to their therapy and,
Table 3 HRQoL (EQ-5D, EQ-VAS, Q-LES-Q-SF) (Continued)
Poor 141 (49.1) 25 (10.6) 120 (41.5)
Fair 87 (30.3) 97 (41.3) 111 (38.4)
Good 16 (5.6) 90 (38.3) 28 (9.7)
Very good 1 (0.3) 22 (9.4) 3 (1.0)
Overall life satisfaction and contentment 2.3 ? 0.8 3.5 ? 0.8 2.5 ? 0.8 <0.0001 b a < c < b
HRQoL = health-related quality of life; MDD =major depressive disorder; EQ-5D = European quality of life-5 dimensions; EQ-VAS = European quality of life visual
analog scale; Q ? LES-Q-SF = the quality of life enjoyment and satisfaction questionnaire short form.
aTukey ? s post-hoc test.
bDifference among MDD groups (ANOVA).
cEQ-5D index score = 1(0.164 + 0.003 ? M2 + 0.274 ? M3 + 0.058 ? SC2 + 0.078 ? SC3 + 0.045 ? UA2 + 0.134 ? UA3 +0.049 ? PD2 + 0.132 ? PD3 + 0.044 ? AD2 + 0.102 ?
AD3 + 0.345 ? N3 + 0.014 ? I2sq).
Where, M2 = dummy for mobility level 2, M3 = dummy for mobility level 3, SC2 = dummy for self-care level 2, SC3 = dummy for self-care level 3, UA2 = dummy for
usual activity level 2, UA3 = dummy for usual activity level 3, PD2 = dummy for pain/discomfort level 2, PD3 = dummy for pain/discomfort level 3, AD2 = dummy
for anxiety/depression level 2, AD3 = dummy for anxiety/depression level 3, N3 = 1 if there is any level 3, otherwise N3 = 0, I2sq = the square of 1 minus the
number of level 2s.
dSumming only the first 14 items to yield a raw total score.
Each item is calculated as 1 = very poor, 2 = poor, 3 = fair, 4 = good, 5 = very good.
eQ-LES-Q-SF index score = (Q-LES-Q-SF total score ? 14)/56.
Note: Data are represented as mean ? standard deviation or number of patients (%).
Table 4 Results of stepwise multiple regression analysis: Association between depression and somatic symptoms
subscales and the quality of life
Variable New MDD (N = 287) Remitted MDD (N = 235) Non-remitted MDD (N = 289) Total (N = 811)
Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value
DS score −0.012 <0.0001 −0.010 <0.0001 - - −0.008 <0.0001
SS score −0.006 0.0173 −0.004 0.0340 −0.016 <0.0001 −0.009 <0.0001
Bech score −0.012 0.0012 - - - - - -
Gibbons score - - - - −0.017 <0.0001 −0.008 <0.0001
MDD =major depressive disorder; DS = depression subscale of the depression and somatic symptoms scale (DSSS); SS = somatic subscale of the DSSS.
Stepwise regression analysis using the full set of variables of the DSSS adjusted by age and sex:
Model 1: QoL (EQ-5D index score|New) = a + b1(DS score) + b2(SS score) + b3(Bech) + b4(Age) + b5(Sex).
Model 2: QoL (EQ-5D index score|Remitted) = a + b1(DS score) + b2(SS score) + b3(Age) + b4(Sex).
Model 3: QoL (EQ-5D index score|Non-remitted) = a + b1(SS score) + b2(Gibbons) + b3(Age) + b4(Sex).
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therefore, their HRQoL is comparable to the value re-
ported for non-responders.
Impact of somatic symptoms on HRQoL
Residual somatic symptoms could be another possible ex-
planation for the worse HRQoL in the non-remitted
group compared with those of other studies. In our subset
analyses, after controlling for depression symptom scores,
patients with severe somatic symptoms had significantly
worse HRQoL than those who had mild/moderate som-
atic symptoms. Even non-remitted patients with mild/
moderate somatic symptoms showed comparable EQ-5D
index scores to those in remission. This finding indicates
that residual somatic symptoms highly influence our
patient-reported outcomes.
Several investigators have reported that the presence
of somatic symptoms, including painful physical symp-
toms (PPS), is associated with greater depression severity
and poor HRQoL [33-35]. Fava et al. [33] examined the
effect of antidepressant medication on PPS in depressed
patients, demonstrating that improvements in the PPS
were linked to higher remission rates. Other studies
showing the association between PPS and HRQoL sug-
gested that patients with positive PPS at the baseline
presented 10% ? 15% lower HRQoL scores (EQ-VAS of
42.2 ? 43.0) than those with negative PPS (EQ-VAS of
52.9 ? 60.4) [34,35]. The presence of PPS is still
associated with less improvement in HRQoL when ad-
justed for depression severity [1,36].
Co-existing pain in depressed patients is highly prevalent
and more likely to be underdiagnosed and undertreated
because of the presence of the depression [37]. The preva-
lence of co-existing PPS in depressed patients ranges from
43% to 73%, varying by country [35,38-40]. In particular,
52% of patients with depression in Asia reported having
positive PPS [35]. Despite this awareness, more than 80%
of patients suffering from PPS were not prescribed con-
comitant treatment for their pain management [35]. Inter-
estingly, the health condition with the largest negative
impact on the HRQoL in the general population is pain,
followed by depression, osteoarthritis, and anxiety [32].
Due to depressive symptoms or co-existing somatic symp-
toms, including PPS, depressed patients may be at higher
risk of an impaired HRQoL. Therefore, physicians or other
health care providers working with depressed patients
should pay careful attention to somatic symptoms as well
as classical depressive symptoms if such patients are seek-
ing help regarding their depression.
Comparison between preference-based and disease-
specific HRQoL
In our present study, subjects showed lower Q-LES-Q-SF
scores as disease-specific QoL measures than those of pre-
vious studies. The scores were 46.5% in the remitted
group and 36.7% in the non-remitted group, whereas pre-
vious studies reported Q-LES-Q-SF scores of 52%? 54% in
patients with depression and 74%? 79% in subjects that
had once had depression [41,42]. The discrepancy may be
related to the different levels of severity between the stud-
ies. Previous investigations assessed the disease-specific
QoL in patients with chronic major depression or dys-
thymia, whereas it was assessed in subjects with more severe
depression in university hospital settings in our study.
HRQoL and suicidal thoughts/suicide attempts
In general, QoL is measured on a scale from 0 (deceased)
to 1 (completely healthy), indicating that death is the
worst state that people can imagine [19]. An impaired
HRQoL is also significantly associated with both suicidal
Table 5 Quality of life by somatic symptom severity
Variable Overalla Remitted MDD Non-remitted MDD
SS ≥ 8
(n = 277)
SS < 8
(n = 279)
p-valueb SS ≥ 8
(n = 28)
SS < 8
(n = 155)
p-valueb SS ≥ 8
(n = 118)
SS < 8
(n = 67)
p-valueb
EQ-5D index score 0.54 ? 0.24 0.75 ? 0.12 0.0017* 0.65 ? 0.19 0.79 ? 0.07 0.0139* 0.52 ? 0.24 0.72 ? 0.14 0.0015*
EQ-VAS 49.32 ? 20.57 69.03 ? 17.56 0.0003* 61.29 ? 15.69 75.50 ? 16.18 0.0372* 47.79 ? 20.68 59.67 ? 16.91 0.2218
Q ? LES-Q-SF index score 0.38 ? 0.14 0.55 ? 0.15 0.0008* 0.48 ? 0.13 0.60 ? 0.16 0.9300 0.38 ? 0.14 0.49 ? 0.12 0.2973
MDD =major depressive disorder; SS = somatic subscale of the depression and somatic symptoms scale; EQ-5D = European quality of life-5 dimensions;
EQ-VAS = European quality of life visual analog scale; Q ? LES-Q-SF = the quality of life enjoyment and satisfaction questionnaire short form.
aPatients aged 40 years or older.
bThe difference between groups was derived from ANCOVA adjusted for depression symptom scores.
*Significance level p < 0.05.
Table 6 Association between suicidal thoughts/suicide
attempts and disease severity and HRQoL
Variable Suicidal thoughts Suicide attempts
ORa (95% CI) ORa (95% CI)
Groups by depression severity
Remitted Reference Reference
Non-remitted 2.55 (1.50? 4.33) 2.14 (1.08 ? 4.25)
New visit 1.56 (0.90? 2.70) 1.21 (0.59 ? 2.47)
EQ-5D index score 0.30 (0.12? 0.75) 0.21 (0.08 ? 0.57)
EQ-5D = European quality of life-5 dimensions; OR = odds ratio;
CI = confidence interval.
aAdjusted for age and DSSS score.
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thoughts and suicide attempts [43]. One study using a
population-based data survey showed that people with an
EQ-5D index score less than 0.7 were 3.4 times more
likely to attempt suicide than those with an index score of
0.8? 1.0 [43]. This study also reported that people with an
EQ-5D index score less than 0.7 had a 9.1 times increased
risk of suicidal thoughts than those with a score between
0.8? 1.0. Our study found a comparable pattern of associ-
ation in patients with depression. Non-remitted patients
with a worse HRQoL showed a more than 2-fold in-
creased risk of suicidal thoughts and suicide attempts than
those in remission. Furthermore, the improvement in
EQ-5D index scores significantly reduced both suicidal
thoughts and suicide attempts in depressed patients. Our
findings indicate the importance of achieving remission in
the treatment of depressed patients, not only for the
improvement of HRQoL, but also for the prevention of
the worst outcomes, such as suicide or death.
Strengths and limitations of the study
Our study has several limitations. First, due to the nature
of a cross-sectional study, we were unable to address the
improvement in HRQoL according to the type of treat-
ment or total duration. However, our investigation involved
multiple sites in Korea, reflecting a similar cohort to a real
world population with depression. Furthermore, by recruit-
ing the new visit group, we attempted to show the initial
baseline characteristics of patients who visited the hospi-
tals. Second, the depression treatment was provided based
on the health care delivery system of each site. The pos-
sible differences between sites might have affected our
HRQoL results. To minimize unintended bias, we re-
cruited the same number of patients from each site.
Conclusions
We evaluated the HRQoL by disease severity in patients
with depression. Non-remitted MDD patients with more
severe somatic symptoms suffer from a poorer HRQoL and
have more clinical symptoms, emphasizing the importance
of achieving remission in the treatment of subjects with
MDD in order to improve their HRQoL. In addition, the
presence of somatic symptoms is significantly associated
with impairment of HRQoL, suggesting that somatic symp-
toms of patients should be carefully evaluated to improve
the preference-based QoL.
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